The needle-free weight-loss pill has arrived: what's approved, and what the numbers really mean
Two GLP-1 weight-loss pills are now approved and a wave more is coming. Here is what they actually deliver, how they compare to the injections, the side effects that get less attention, and why a pill could matter beyond the headline numbers.
The era of the weight-loss pill is no longer coming, it is here. Two oral GLP-1 medicines are now approved: Eli Lilly's orforglipron (Foundayo), cleared in April 2026, and Novo Nordisk's oral semaglutide pill, cleared at the end of 2025. A third, Structure Therapeutics' aleniglipron, posted strong mid-stage results in Nature Medicine and is heading into final trials. In studies the pills drove roughly 11 to 17 percent weight loss, in the same range as some injections, though the figures are trial averages, not promises, and the same GLP-1 side effects apply. This is a health story, not medical advice: anyone considering one should talk to a doctor.
For a decade the most effective weight-loss medicines came with a catch that put many people off: a weekly injection. In 2026 that barrier is falling. The GLP-1 drugs that reshaped obesity treatment now come as a daily pill, two are already approved, and the science behind them suggests pills could end up mattering even more than the headline weight-loss numbers. Here is where things actually stand, with the caveats a responsible read requires.
What is already approved
Two oral GLP-1 medicines have crossed the finish line.
Orforglipron (sold as Foundayo), from Eli Lilly, won FDA approval in April 2026 for adults with obesity, or who are overweight with a related condition. It is a once-daily pill and, importantly, a small molecule, which matters for reasons we will come to. In its main trial, the highest dose produced about 12 percent weight loss over 72 weeks on the measure that assumes people take it as directed, and about 11 percent on the more real-world measure. Roughly six in ten participants lost at least a tenth of their body weight.
Oral semaglutide, the pill version of the drug in Wegovy and Ozempic, was approved slightly earlier, at the end of 2025, and reached people in early 2026. In its trial it delivered around 16.6 percent weight loss when taken consistently, with about one in three participants losing a fifth of their body weight. One technical point worth knowing: this pill is a peptide, the same kind of molecule as the injections, just formulated to survive being swallowed. That makes it different from the new small-molecule pills, again, more on why that matters below.
What is coming next
Behind the approved drugs is a pipeline, and the one drawing the most attention is aleniglipron, from Structure Therapeutics. In a mid-stage (Phase 2b) trial published in Nature Medicine in June 2026, its highest dose produced up to 11.3 percent weight loss beyond placebo at 36 weeks, and participants who continued in an extension study kept losing, reaching around 16 percent total over a longer follow-up. Structure says it expects to begin final-stage Phase 3 trials in the second half of 2026. It is a small-molecule pill like orforglipron, and it is not yet approved, so its numbers, while promising, are earlier and less settled than the approved drugs'.
How well do they actually work?
In the same ballpark as each other, and competitive with some injections, but the comparison is trickier than it looks. These are separate trials with different designs, doses and participants, so it is not fair to line them up and declare a winner. Two other cautions matter. First, trial results are averages: plenty of people lost less than the headline figure, and some lost more. Second, drug trials report weight loss two ways, one assumes you take every dose as prescribed, the other reflects what happens across everyone including those who stop or slip. The rosier number is the first kind, so treat any single percentage as a best case rather than a guarantee.
The catch: side effects
The pills carry the same downside as the rest of the GLP-1 family: stomach trouble. Nausea, vomiting, diarrhoea and constipation were the most common complaints across all of these drugs, generally mild to moderate and worst during the weeks when the dose is being increased. They were common enough to matter: in the orforglipron and aleniglipron trials, the share of people who stopped because of side effects rose with the dose, reaching around 10 percent at the highest dose, compared with roughly 3 percent on placebo. These medicines also carry the same class-wide cautions as other GLP-1 drugs, which is one of several reasons they are prescription-only and not something to start on your own.
Why a pill matters more than it sounds
The obvious appeal of a pill is that it is not a needle, which will bring in people who were never going to inject themselves. But the deeper reason is manufacturing. The injectable GLP-1s are peptides, which are relatively complex and capacity-limited to produce, and shortages have dogged them. The new small-molecule pills (orforglipron and aleniglipron) can be made with conventional chemistry in standard pharmaceutical plants, with no cold chain required, which analysts expect to make them cheaper and easier to produce at scale. Exact savings figures floating around are industry estimates rather than confirmed numbers, so treat them with caution, but the direction is clear: pills that are simpler to manufacture could widen access in a way the injections never quite managed. The one exception is the oral semaglutide pill, which is still a peptide and so does not get that manufacturing advantage.
The bottom line
The needle-free weight-loss drug is real and, for two of them, already on pharmacy shelves, with more in late-stage testing. The weight-loss figures are genuinely in injection territory, the side effects are real and mostly gastrointestinal, and the biggest long-term effect may be on supply and price rather than on the scale. What this article is not is a recommendation: which drug, if any, is right for a given person is a decision for them and their doctor, weighing benefits, side effects and medical history. For more, see the Science section.
A blood test can now help diagnose Alzheimer's. Here's what that really means
Diagnosing Alzheimer's used to require an expensive brain scan or a spinal tap. In 2026 a simple blood test crossed from the research lab into the clinic, sharply improving how accurately doctors can identify the disease. It is a genuine turning point, and also not a crystal ball. Here is what these tests do, and what they do not.
The FDA just approved the first mRNA flu shot, a year to the day after Washington cut off federal mRNA vaccine funding
On 5 August 2026 the FDA approved mFlusiva, Moderna's mRNA influenza vaccine and the first of its kind for seasonal flu. It arrived a year after the government cancelled roughly $500 million in mRNA work, and only after the agency's own vaccine chief moved to block it, then reversed. Here is what the shot does.
For the first time, we can see whirlpools on the Sun's surface. They may explain why its atmosphere is so strangely hot
The world's largest solar telescope has taken the sharpest images ever of the Sun's surface and caught something long predicted but never seen there: tiny plasma whirlpools about 20 km across, the wave-curl seen in ocean waves and clouds. They may help solve a decades-old mystery, but here is what it does not prove.